Bethany B Davis MD

Psychiatry•Atlanta, GA

Physician

Join to View Full Profile

6065 Roswell Rd Ste 820Atlanta, GA 30328
Phone+1 470-223-0062

Summary

Dr. Bethany Davis is a psychiatrist based in Atlanta, GA. She completed her psychiatry residency at Emory University School of Medicine after an internship at the Children's Hospital of Philadelphia and graduating from the Medical University of South Carolina. Since 2005, she has been practicing at her own practice, Bethany B Davis MD, LLC, and she is also employed as a psychiatrist with Synexus Clinical Research. Her research includes a publication on maintenance therapy for bipolar I disorder in "Bipolar Disorders" and participation in multiple clinical trials focusing on treatments for schizophrenia.

Education & Training

Emory University School of MedicineResidency, Psychiatry, 2002 - 2005
Childrens Hospital of PhiladelphiaInternship, Transitional Year, 1999 - 2000
Medical University of South CarolinaClass of 1999

Certifications & Licensure

GA State Medical License 2002 - 2025
SC State Medical License 2005 - 2007
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia Start of enrollment: 2021 Aug 09
COMPLETED
PHASE3
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) Start of enrollment: 2021 Jun 02
COMPLETED
PHASE3
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Start of enrollment: 2021 Nov 12
COMPLETED
PHASE3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Start of enrollment: 2022 Mar 07
RECRUITING
PHASE3
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
TERMINATED
PHASE3
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine Start of enrollment: 2018 Dec 14
Completed
Phase 3
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Start of enrollment: 2017 Jun 15
COMPLETED
PHASE3
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features Start of enrollment: 2018 Jun 15
Completed
Phase 3
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia Start of enrollment: 2019 Feb 15
Terminated
Phase 2, Phase 3
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia Start of enrollment: 2019 Apr 15
Completed
Phase 2
Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo Start of enrollment: 2019 Dec 14
Completed
Phase 2
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Start of enrollment: 2022 Jun 30
COMPLETED
PHASE2
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia Start of enrollment: 2022 Sep 02
ACTIVE_NOT_RECRUITING
PHASE2
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Start of enrollment: 2021 Sep 30
COMPLETED
PHASE3
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Start of enrollment: 2021 Oct 08
COMPLETED
PHASE3
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Start of enrollment: 2020 Sep 15
TERMINATED
PHASE3
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Start of enrollment: 2020 Sep 15
COMPLETED
PHASE3
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Start of enrollment: 2023 Jan 05
TERMINATED
PHASE3
Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD Start of enrollment: 2019 Oct 17
COMPLETED
PHASE3
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder Start of enrollment: 2018 Nov 19
Completed
Phase 3
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. Start of enrollment: 2019 Nov 15
COMPLETED
PHASE3
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia Start of enrollment: 2018 Jul 30
Terminated
Phase 3
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® Start of enrollment: 2019 Apr 29
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder.
Roger S McIntyre, Bethany Davis, Jane Rodgers, Ludmyla Rekeda, Julie Adams
Bipolar Disorders. 2024-08-01
65 citations
Treatment of Type 2 Diabetes in Childhood Using a Very-Low-Calorie Diet
Steven M. Willi, Kelley Martin, Farrah M. Datko, Bethany P. Brant
Diabetes Care. 2004-02-01
45 citations
Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes
Steven M. Willi, Adele Kennedy, Bethany P. Brant, Penny Wallace, Nikki Lynn Rogers
Diabetes Research and Clinical Practice. 2002-11-01